Pan-Mass Challenge Raises $56 Million for Dana-Farber Cancer Institute

Pan-Mass Challenge Raises $56 Million for Dana-Farber Cancer Institute

The Pan-Mass Challenge, a two-day cycling fundraiser in August that offered participants the choice of twelve routes of varying distances, raised a record $56 million for the Boston-based Dana-Farber Cancer Institute in support of adult and pediatric patient care and cancer research.

The largest contribution ever from PMC to Dana-Farber is $5 million more than the amount raised by the challenge in 2017 for the institute's Jimmy Fund. As Dana-Farber's largest contributor, PMC — which is sponsored by New Balance and the Red Sox Foundation — accounts for 54 percent of the Jimmy Fund's annual revenue. Since its inception in 1980, the challenge has raised a total of $654 million in support of Dana-Farber's research initiatives and clinical trials.

"The impact of the PMC community is truly unparalleled. The magnitude of a $56 million gift raised by ten thousand PMC riders and volunteers is obvious to anyone who funds cancer research," said PMC founder and executive director Billy Starr. "For thirty-nine years, we've increased our fundraising goals, and each year the dedication of an ever-expanding PMC family exceeds even our highest expectations. [This year] is no exception — [and the] gift will further enable Dana-Farber's global advancements in cancer research, care, and treatment."

"I am honored to be a part of the PMC family and am in awe of how participants continue to push themselves and increase their contributions to PMC and Dana-Farber," said Laurie H. Glimcher, president and CEO of the institute. "We're particularly grateful for this year's astounding $56 million gift, which is vital to our ongoing work. The PMC plays a very important role in Dana-Farber's fight against cancer by providing critical funds to sustain our mission and empowering groundbreaking work across our laboratories and clinics. The funds raised enable Dana-Farber to invest in bold research that leads to discovering better cancer treatments through drug development and providing the very best patient care."